18983288589(微信同号)
18983288589(微信同号)
18908392210(微信同号)
18980413049
ChiCTR-INR-16009598
正在进行
/
/
/
2016-10-25
/
/
冠心病
基于智能手机的家庭心脏康复和冠心病患者二级预防的随机对照研究
基于智能手机的家庭心脏康复和冠心病患者二级预防的随机对照研究
The aim of the clinical trial is to assess the effects of smartphone-based cardiac rehabilitation and secondary prevention program on the short-term and long-term outcomes of post-PCI CHD patients, as well as its effects on improvement of quality of life, enhancing management of risk factors and medication, increasing cost benefits and reducing hospital readmissions.
随机平行对照
治疗新技术
The Project Manager will be supplied with one randomization envelope for each participant. It is the responsibility of the Project Manager to ensure that these randomization envelopes are safely stored, but readily available to the relevant staff. Once patients have signed the Consent Form, they will provided with a
/
Curtin University PhD research funding
/
300
/
2016-05-06
2019-05-05
/
Eligible participants will be patients diagnosed with coronary heart disease and received PCI. Inclusion criteria are that the participant must: Diagnosed by a clinician, have met criteria for diagnosis of CHD; Received PCI therapy during this admission; Aged between 18-70 years; Have an active smartphone, and have sufficient Chinese language proficiency to reading, speaking and listening; Able to operate smartphone for the purposes of trial; Living with at least one caregiver or guardian in the household; Presence of normal hemodynamics with a resting ejection fraction ≥ 50%; Able to individually consent; Not participating in any other clinical trial.;
登录查看Unable to be involved in clinical follow up and treatment; Unable to operate smartphone for the purpose of the trial (eg, vision, hearing, cognitive or dexterity impairment); Had no experience with WeChat application; Have no internet connection at residence and smartphone Wi-Fi connection; Have contra-indication to CR.;
登录查看Curtin University
/
BioArtMED2024-11-23
新康界2024-11-23
Rimonci2024-11-23
肝脏时间2024-11-23
精准药物2024-11-23
亚泰制药2024-11-23
昌郁医药2024-11-22
上海和誉生物医药科技有限公司2024-11-22
云顶新耀2024-11-22
金斯瑞生物2024-11-22